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doi:10.1016/j.jtcvs.2007.05.059nfections involving ascending aortic grafts are extremely difficult to eradicate
and are frequently lethal. Successfully treating this complication is always
challenging and is especially problematic when the infection extends into
djacent prosthetic material in the aortic root—as in patients with composite valve
rafts (CVGs)—or in the aortic arch. Although antibiotics are a critical component
f treatment, they are rarely effective as the sole form of therapy. Among the many
atients described in reports of ascending aortic graft infection, only a handful have
een successfully treated with antibiotics alone.1-4 We1 previously reported that o
patients with infected ascending/arch grafts in whom nonoperative treatment was
ttempted, medical treatment ultimately failed in 3 (43%), necessitating operation.
n 1995, Gott and associates4 reported that of 7 patients treated nonoperatively 
VG endocarditis, only 2 (29%) survived. These authors later reported using
ntibiotics alone to successfully treat 5 patients with Marfan syndrome who had
arly CVG endocarditis, but the authors emphasized that this treatment approach is
ot sufficient in patients with severe prosthetic infections.3 In their brief commu
ication in this issue, Akowuah and colleagues5 describe treating 2 patients wi
ntibiotics alone; both patients died. The dismal results of nonoperative manage-
ent justify aggressive surgical treatment of infected ascending aortic grafts.
The cornerstone surgical strategy for treating patients with infected peripheral
ascular grafts is graft removal and extra-anatomic bypass. Although technically
ossible,6 extra-anatomic bypass is not suitable for managing ascending aortic 
nfections; therefore, the surgical options involve either salvaging the existing graft
r replacing it in situ. In either case, the need to leave prosthetic material in an
nfected surgical field makes it difficult to eradicate the infection. In 1984, Hargrove
nd Edmunds7 introduced guidelines to address this problem, emphasizing the 
or prompt and thorough surgical debridement, antiseptic irrigation, and appropriate
ntibiotic therapy. Notably, these early recommendations—which were based on the
uthors’ pioneering experience with only 4 patients—remain the central guiding
rinciples for treating patients with infected thoracic aortic grafts today.5
Beyond these well-established principles of debridement and antimicrobial treat-
ent, the options for dealing with an infected ascending aortic graft are character-
zed by the two main areas of controversy: whether to remove the infected graft and,
f it is removed, what to replace it with. Although evidence-based practice guide-
ines are becoming available for many issues cardiothoracic surgeons face, 8 it is
nlikely that such guidelines will ever be established for managing this challenging
roblem. The literature on surgical treatment of ascending aortic graft infection fails
o provide even the lowest level of evidence (level C, consensus expert opinion) on
hich to base a concrete recommendation. Although plenty of expert opinion is
vailable, consensus is clearly lacking. The accumulated expert opinion, however,
omprises a valuable armamentarium that surgeons can use when planning treat-
ent for their patients. In their report, Akowuah and colleagues5 illu trate the valu
f using individualized treatment strategies in different clinical situations; this
rovides a welcome opportunity to review the available options.
raft Removal and Replacement With a Synthetic Graft
nfected ascending aortic grafts have often been replaced with new synthetic grafts,
specially during the era before bioprosthetic alternatives became commercially
vailable. In cases in which the extent of replacement has been relatively limited,
utcomes have generally been very good. In 1990, we1 reported using new Dacron









































































































Lube grafts or patches to treat postoperative aortic infections
n 10 patients; there were no early deaths, 1 late death, and
o cases of recurrent infection. Along with other groups that
ave used synthetic grafts to replace infected ascending aortic
rafts, we have emphasized the value of thorough debridement
nd other measures to reduce the chance of recurrent infection,
ncluding postoperative mediastinal irrigation with an antibac-
erial solution and coverage of the graft with viable tissue
edicles.7,9-11
Completely removing infected prosthetic material and
eplacing it with a new graft is particularly challenging
hen the infection involves a CVG. Combining root rere-
lacement with aggressive debridement in an inflamed and
ecrotic field often results in prolonged operations with
ubstantial blood loss. Given the technical challenges of this
rocedure and the poor condition of many of these patients,
t is not surprising that these operations have been associ-
ted with poor outcomes. In our cumulative experience, 5 of
he 11 patients with infections who had new CVGs placed
ied within 30 days (46%).1,12 Other groups have reporte
imilarly disappointing results when new CVGs were used
o replace infected CVGs.4,13
A few groups, however, have achieved very satisfying
esults using this approach to treat CVG infection. Ralph-
dwards, David, and Bos14 reported excellent early surviva
10/11, 91%) in patients in whom CVGs were used to
eplace infected grafts. This series was noteworthy for the
uthors’ use of extensive debridement that often required
econstruction of the left ventricular outflow tract with
lutaraldehyde-fixed bovine pericardium and lengthening of
he coronary arteries with saphenous vein or synthetic
rafts. However, in a subsequent report,15 the authors noted
25% incidence of recurrent prosthetic valve endocarditis
n their series; this group currently uses homograft roots
henever available. Hagl and colleagues16 have also re-
orted excellent early survival in 23 patients treated with
ggressive debridement and replacement with new CVGs;
oreover, all but 1 patient in the series remained free of
ecurrent endocarditis during follow-up. Because of these
esults, the Mount Sinai group continues to use CVGs in this
etting, except in patients with contraindications to antico-
gulation, who are better served by having the infected
VG replaced with a homograft.
raft Removal and Replacement With a Tissue Graft
everal groups currently favor replacing infected ascending
ortic prostheses with cryopreserved aortic homografts.2,3,17-19
lthough homografts are not impervious to endocarditis,19-21
hey appear to be more resistant to infection than synthetic
rafts, perhaps because homografts allow better antibiotic pen-
tration and inherently attract immune cells.17 Retrospective
ata have suggested that, compared with using synthetic grafts,
sing cryopreserved homografts for treating vascular infec- o
40 The Journal of Thoracic and Cardiovascular Surgery ● Octoions is associated with improved outcomes, including better
limination of infection, fewer postoperative complications,
nd longer disease-related survival.22 The malleability of th
omograft tissue is considered a technical advantage be-
ause it enables the graft to conform to a widely debrided
nnulus.18 In situ replacement of contaminated or infec
rafts in the aortic root, ascending aorta, and transverse
ortic arch has been associated with encouraging early and
idterm results; although available reports only describe
mall groups of patients, these patients’ collective early
urvival exceeds 90%.2,3,15,18,23-25
One commonly cited disadvantage of using homografts
s their predisposition to progressive deterioration and ulti-
ate need for rereplacement.16,19 Another limitation is th
elatively low tensile strength of the homograft tissue; be-
ause of this, it is extremely important to avoid anastomotic
ension caused by using an inappropriately short graft. Un-
ortunately, in many cases, a single homograft will not reach
he distal ascending aorta or transverse arch.18 Gaps be-
ween the distal end of the homograft and the native aorta
an be bridged with a segment of synthetic graft, but this
ssentially defeats one of the purposes of selecting a tissue
raft in the first place. Extensive aortic replacement can be
ccomplished by using total arch homografts, but these are
arely available.23 To address this problem, Lytle and c-
eagues18 have described using 2 standard aortic root -
ografts to perform hemiarch replacement; reversing the
istal homograft after its valve has been removed allows the
arger proximal end to be used for the arch anastomosis.
Although tissue replacement of infected CVGs has tradi-
ionally required the use of homografts, porcine xenograft roots
ave emerged as another option for replacing the infected root.
kowuah and colleagues5 successfully treated 1 of their p-
ients by using a xenograft root. These grafts have the advan-
age of on-the-shelf availability and have been particularly
seful in areas of the world where homografts are difficult or
mpossible to obtain.26,27 Compared with homografts, xeno-
rafts appear to be less susceptible to progressive degeneration.
ohammadi and colleagues28 recently described outstanding
reedom from structural valve deterioration in a large series of
atients who received porcine xenografts. Valve dysfunction
eveloped in only 1 of 133 patients who had porcine xenograft
oot implantations. This problem was due to a leaflet tear and
equired reoperation 12 years after the initial implantation.
orcine xenograft endocarditis is also rare28; although thes
rafts have a synthetic sewing cuff, their treatment with glu-
araldehyde may confer resistance to infection.
Porcine xenografts, however, are even shorter than most
omograft roots; therefore, an additional segment of graft is
enerally required to bridge the gap between the distal end
f the xenograft and the patient’s aorta. As described above,
his can be accomplished with a segment of synthetic graft










































































































Lenograft roots are not recommended for use in cases that
equire extensive annular debridement; the irregular base
or the proximal suture line can cause significant distortion
f the valve and produce regurgitation.16
alvaging the Original Graft
egardless of the type of conduit used, removing and re-
lacing an infected ascending aortic graft is a major under-
aking that carries substantial risk of morbidity and mortal-
ty. The alternative surgical approach that Akowuah and
olleagues5 highlight— extensive mediastinal debridemen
nd irrigation—has been used successfully by many groups
Table 1).1,2,7,12,13,29-35 All of their reports include patie
ith ascending aortic grafts, many of whom also received
n arch graft, CVG, or separate aortic valve prosthesis.
hese patients’ collective early survival is 91%. Nearly all
f the reports include follow-up of at least 2 years, and most
pecifically document the absence of recurrent graft infec-
ion after the definitive procedure.
The techniques used to achieve these encouraging results
hare several common features but also vary substantially.
ost reports emphasize the need for thorough debridement
f all surrounding infected and necrotic material as well as
ntraoperative irrigation with povidone–iodine or antibiotic
olution. Catheters are occasionally left in the mediastinum
o facilitate postoperative irrigation.30,32,33 The technique
escribed by Kawachi and colleagues34 is unique in tha
hey used fibrin glue containing gentamicin to fill dead
pace. Most groups covered the graft with a vascular tissue
ap; omentum was the most common flap, although muscle
aps were also frequently used. Tissue coverage was often
erformed immediately after mediastinal debridement and
rrigation; however, several authors used staged procedures,
erforming debridement during the first operation and tissue
ABLE 1. Reports describing surgical treatment to salvage
nfected ascending aortic grafts
uthor and year No. of patients Early survivors
argrove and Edmunds, 19847 1 1
eguin and Loisance, 198529 2 2
oselli et al, 19901 16 14
rabatsch and Hetzer, 199530 1 1
havanon et al, 199831 1 1
akajima et al, 199913 4 3
oselli et al, 19992 3 2
athes et al, 200033 1 1
uciani et al, 200132 1 1
awachi et al, 200234 1 1
eMaire et al, 200212 1 1
itra et al, 200535 9 9
kowuah et al, 20075 5 5
otal 46 42 (91%)overage and definitive wound closure during the second u
The Journal of Thoracicperation.33-35 In a few cases of staged treatment, the ste
ound was left open to facilitate a period of mediastinal
acking and frequent dressing changes before the second
peration was performed.7,13
Several factors have been discussed in the context of
electing patients who are likely to benefit from graft-
paring procedures. This approach is particularly well-
uited for patients with poor physiologic reserve, who are
nlikely to tolerate graft removal.32 Akowuah and col-
eagues5 reserved this approach for patients with gr
ontaminated from adjacent sternal wound infections; al-
hough graft-sparing operations seem ideal for this type of
atient, we and other groups have applied this approach
ithout using sternal wound infection as a criterion.1,13,35
he severity of graft involvement is another aspect to con-
ider. In a case reported by Hargrove and Edmunds,7 the
ecision not to remove the graft was based largely on the
act that the “suture lines were completely covered with
ealthy autogenous tissue.” Although intact grafts with un-
xposed suture lines are desirable, we and other authors
ave used this approach in selected patients with contami-
ated anastomoses, including those with anastomotic leaks,
seudoaneurysms, and aortocutaneous fistulas.1,2,12,29,34 In
ost cases, the culprit anastomotic defects were treated by
rimary repair. Kawachi and colleagues34 used Dacron
atches to repair suture line dehiscence at the distal anas-
omosis. We1 have avoided leaving the graft in place
atients with antibiotic-resistant infections (indicted by per-
istent positive blood cultures), severe graft deformity, pros-
hetic valve vegetations, or adjacent diseased aortic seg-
ents that needed replacement (because of severe aortic
alve regurgitation, large aneurysm, or aortocardiac fistula,
or example).
trategies to Prevent Recurrent Infection
rrespective of how the infected graft is specifically dealt with,
everal strategies are commonly used to prevent recurrent
nfection. Irrigation with antiseptic solutions—principally
ovidone–iodine or antibiotics—is a ubiquitous component of
reatment, although the mode of delivery has varied. At a
inimum, the aortic graft and surrounding mediastinal tissues
re thoroughly irrigated during the operation. Mediastinal cath-
ters are commonly placed to enable postoperative irrigatio32
inally, if the sternum is left open after the debridement pro-
edure, the mediastinum can be packed with sponges soaked in
ovidone–iodine.13 When povidone–iodine is used for posto-
rative irrigation, care is taken to avoid iodine toxicity and
esulting hepatic dysfunction. Precautions include using dilute
olutions (eg, 1% povidone–iodine) for irrigation while mon-
toring daily serum iodine concentrations (normal range, 4 to 8
g/dL) and liver enzyme levels.13,32,33
Other methods of delivering local antibiotics may also beseful. Some authors have used gentamicin-impregnated










































































































Lbrin glue to seal anastomoses and fill dead space24,34
hen using synthetic grafts for replacement, we routinely
oak gelatin-sealed Dacron grafts in rifampin before im-
lantation; although this practice has not been adequately
tudied in the setting of thoracic aortic reconstructions,
ncouraging results have been reported in the peripheral
ascular surgery literature.36,37 The development of effec-
ive, commercially available antibiotic-bonded grafts would
e useful for these cases.
It may also be helpful to avoid using suture and rein-
orcement materials that are likely to harbor bacteria. When
orking in a contaminated field, we favor using monofilament
uture instead of braided suture. We also avoid synthetic ma-
erials when buttressing anastomoses and cannulation sites;
ledgets and reinforcing strips can be made from excess ho-
ograft tissue, autologous pericardium, or glutaraldehyde-
reated bovine pericardium instead of Teflon felt.22
Most reports describe using viable tissue to obliterate
ead space and provide vascularized coverage of the graft.
ccasionally, this can be accomplished by mobilizing local
issues, such as the thymus and pericardial fat pads.1 More
ommonly, coverage is achieved with a pedicled omental
r muscle flap. Omentum is particularly popular because,
n patients who have not had previous abdominal sur-
ery, omentum can be easily accessed by extending the
ternotomy incision into the abdomen for a short dis-
ance.7,9,11-13,25,29,30,32,33 The blood supply to the omentu
s preserved by basing the pedicle on the right gastroepip-
oic artery. In addition to filling dead space, the vascularized
mental pedicle improves oxygen supply to the region,
nhances immunologic response, increases antibiotic deliv-
ry, and absorbs wound secretions that can serve as sub-
trates for bacterial growth.9,29,32 Muscle flaps used in p-
ients with ascending aortic graft infection have included
ectoralis major, rectus abdominis, latissimus dorsi, and
erratus anterior.1,7,13,31,33,35 Occasionally, a combination
f flaps is necessary to achieve adequate coverage. The
ortic graft can be covered with a vascularized flap during
he original debridement/graft replacement procedure or in a
elayed manner after a period of closed mediastinal irriga-
ion or open wound care.
The final aspect of preventing recurrent graft infection is
dministering systemic antibiotics. In most cases, a period of
ntravenous antibiotic administration is followed by long-term
ral antibiotic therapy. Choices regarding the length of antibi-
tic treatment remain arbitrary, and the efficacy of long-term
ntibiotics remains unproven.7 Approaches to antibiotic trea-
ent have ranged from a 7-day course of intravenous antibi-
tics without subsequent oral therapy34 to lifelong antibioti
reatment.1,7,33 Although we continue to advocate lifelong s-
ressive antibiotic therapy—especially in patients with resid-
al synthetic graft material—there is admittedly no evidence
upporting this practice.12 It certainly seems reasonable to limit a
42 The Journal of Thoracic and Cardiovascular Surgery ● Octohe length of antibiotic treatment in patients whose infected
rafts have been replaced with homografts. In many reported
ases, the approach to antibiotic treatment was individualized
ccording to multiple clinical factors, including severity of
nfection, comorbid conditions, the specific pathogens in-
olved, and the postoperative course. Hagl and colleagu16
ecommend a strategy that is based on operative findings: if
urgical cultures are positive, patients would receive at least 6
eeks of antibiotic therapy; if the cultures are negative but
rganisms are seen on Gram stain, patients would receive at
east 4 weeks of antibiotic treatment; and if cultures and Gram
tain are negative, antibiotic treatment would be continued for
nly 2 weeks.
reventing Graft Infection
ecause of the dire consequences of thoracic aortic graft
nfection, we maintain an aggressive approach to prophy-
axis in all patients undergoing thoracic aortic repairs, de-
pite the absence of supportive evidence. Specifically, we
outinely apply topical cephalosporin or vancomycin pow-
er to the graft and continue intravenous antibiotics post-
peratively until all chest drains and central venous lines are
emoved. It is important to recognize that the threat of aortic
raft infection persists long after hospital discharge. One
nusual aspect of Akowuah and colleagues’ series5 i  the
hort interval between the initial operation and the graft
nfection (range 6-30 days). Many other series have dem-
nstrated that the risk of aortic graft infection continues for
ears after the initial operation.1,2,7,12,14,16 We believe tha
his risk justifies an aggressive approach to antibiotic pro-
hylaxis whenever patients with aortic grafts require inva-
ive procedures that produce bacteremia, such as bronchos-
opy, colonoscopy, and dental procedures, regardless of the
ength of time since the graft was implanted; we favor
eriprocedural intravenous broad-spectrum antibiotics over
ral antibiotic prophylaxis in these patients. Experimental
odels are desperately needed to improve strategies for
hort- and long-term prevention of thoracic aortic graft
nfection.38
onclusions
t is notable how little evidence is available to guide sur-
eons in treating patients with ascending aortic graft infec-
ion. There are, however, many established options for
anaging the infected graft, all of which have their place
ithin the surgical armamentarium. In situ replacement can
e effective but is often associated with substantial morbid-
ty and mortality, especially in patients with infected CVGs.
n many cases, existing grafts can be salvaged through a
egimen of aggressive debridement, irrigation, and coverage
ith healthy tissue. Ultimately, the treatment strategy
hould be selected on the basis of relevant clinical factors
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